Skip to content

Study · Not a test of the peptide alone · 2000

4 results

Effects of short-term glucocorticoid deprivation on growth hormone (GH) response to GH-releasing peptide-6: studies in normal men and in patients with adrenal insufficiency.

Pinto AC, Silva MR, Martins MR, Brunner E, Lengyel AM

The Journal of clinical endocrinology and metabolism1 Apr 2000Cited by 4 (Europe PMC)

PMID10770194 (opens in a new tab)DOI10.1210/jcem.85.4.6536 (opens in a new tab)PepBankPUB-10770194
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 01HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In normal men, metyrapone did not significantly alter the GH response to GHRP‑6 compared with placebo.

    In plain wordsIn healthy men, metyrapone did not significantly change the growth hormone response to GHRP‑6 compared with placebo.

    Peptide
    GHRP-6
    Outcome
    No significant changeGH response to GHRP-6 after metyrapone in normal men
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH peak
    39.3 microg/L
    metyrapone
    GH peak
    21.9 microg/L
    placebo

    Source sentences

    Summary
    In normal subjects, metyrapone ingestion did not alter significantly GH responsiveness to GHRP-6 [n = 8; peak, 39.3 +/-7.1 microg/L; area under the curve (AUC), 1958.8 +/- 445.7 microg/min x L; mean +/- SE] compared to placebo (n = 8; peak, 21.9 +/- 4.5; AUC, 1131.0 +/- 229.6).
    1 context sentence
    Summary · context
    The aims of this study were to evaluate GH responsiveness to GHRP-6 1) after metyrapone administration in normal men, and 2) in patients with chronic hypocortisolism after glucocorticoid withdrawal for 72 h.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    After glucocorticoid withdrawal, GH responsiveness to GHRP‑6 in patients with chronic hypocortisolism was significantly lower than in normal subjects pretreated with metyrapone.

    In plain wordsAfter steroid withdrawal, patients with chronic low cortisol had a lower growth hormone response to GHRP‑6 than healthy men given metyrapone.

    Peptide
    GHRP-6
    Outcome
    DecreaseGH response to GHRP-6 after withdrawal versus metyrapone-treated normal subjects
    Study

    n = 16

    Comparator
    Normal subjects pretreated with metyrapone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Interestingly, after glucocorticoid withdrawal, GH responsiveness to GHRP-6 in patients with chronic hypocortisolism was significantly lower than that in normal subjects pretreated with metyrapone.
    1 context sentence
    Summary · context
    The aims of this study were to evaluate GH responsiveness to GHRP-6 1) after metyrapone administration in normal men, and 2) in patients with chronic hypocortisolism after glucocorticoid withdrawal for 72 h.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 03HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In patients with chronic hypocortisolism, GH responses to GHRP‑6 were similar during replacement therapy and after prednisone withdrawal.

    In plain wordsIn patients with chronic low cortisol, the growth hormone response to GHRP‑6 was similar with and without prednisone.

    Peptide
    GHRP-6
    Outcome
    No significant changeGH response to GHRP-6 after glucocorticoid withdrawal in hypocortisolism
    Study

    n = 8

    Comparator
    During replacement therapy
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH peak
    11.8 microg/L
    replacement therapy
    GH peak
    14.4 microg/L
    after prednisone withdrawal

    Source sentences

    Summary
    In patients with chronic hypocortisolism (n = 8), GH responses to GHRP-6 were similar both during replacement therapy (peak, 11.8 +/- 3.9; AUC, 563.2 +/- 208.7) and after withdrawal of prednisone (peak, 14.4 +/- 4.5; AUC, 695.6 +/- 272.9) and did not differ from those in controls.
    1 context sentence
    Summary · context
    The aims of this study were to evaluate GH responsiveness to GHRP-6 1) after metyrapone administration in normal men, and 2) in patients with chronic hypocortisolism after glucocorticoid withdrawal for 72 h.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 04HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In patients with chronic hypocortisolism, GH responses to GHRP‑6 did not differ from those in controls.

    In plain wordsIn patients with chronic low cortisol, the growth hormone response to GHRP‑6 did not differ from that of controls.

    Peptide
    GHRP-6
    Outcome
    No significant changeGH response to GHRP-6 in hypocortisolism versus controls
    Study

    n = 8

    Comparator
    Controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    In patients with chronic hypocortisolism (n = 8), GH responses to GHRP-6 were similar both during replacement therapy (peak, 11.8 +/- 3.9; AUC, 563.2 +/- 208.7) and after withdrawal of prednisone (peak, 14.4 +/- 4.5; AUC, 695.6 +/- 272.9) and did not differ from those in controls.
    1 context sentence
    Summary · context
    The aims of this study were to evaluate GH responsiveness to GHRP-6 1) after metyrapone administration in normal men, and 2) in patients with chronic hypocortisolism after glucocorticoid withdrawal for 72 h.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.